PURPOSE: To compare systemic intravenous and local intratracheal delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA). METHODS: "Neutral" and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular internalization of DOX, ASO and siRNA was studied by confocal microscopy on human lung carcinoma cells. In vivo experiments were carried out on nude mice with an orthotopic model of human lung cancer. RESULTS: Liposomes provided for an efficient intracellular delivery of DOX, ASO, and siRNA in vitro. Intratracheal delivery of both types of liposomes in vivo led to higher peak concentrations and much longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic administration. It was found that local intratracheal treatment of lung cancer with liposomal DOX was more efficient when compared with free and liposomal DOX delivered intravenously. CONCLUSIONS: The present study outlined the clear advantages of local intratracheal delivery of liposomal drugs for the treatment of lung cancer when compared with systemic administration of the same drug.
PURPOSE: To compare systemic intravenous and local intratracheal delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA). METHODS: "Neutral" and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular internalization of DOX, ASO and siRNA was studied by confocal microscopy on humanlung carcinoma cells. In vivo experiments were carried out on nude mice with an orthotopic model of humanlung cancer. RESULTS: Liposomes provided for an efficient intracellular delivery of DOX, ASO, and siRNA in vitro. Intratracheal delivery of both types of liposomes in vivo led to higher peak concentrations and much longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic administration. It was found that local intratracheal treatment of lung cancer with liposomal DOX was more efficient when compared with free and liposomal DOX delivered intravenously. CONCLUSIONS: The present study outlined the clear advantages of local intratracheal delivery of liposomal drugs for the treatment of lung cancer when compared with systemic administration of the same drug.
Authors: U Griesenbach; A Chonn; R Cassady; V Hannam; C Ackerley; M Post; A K Tanswell; K Olek; H O'Brodovich Journal: Gene Ther Date: 1998-02 Impact factor: 5.250
Authors: Vladimir P Torchilin; Tatyana S Levchenko; Ram Rammohan; Natalia Volodina; Brigitte Papahadjopoulos-Sternberg; Gerard G M D'Souza Journal: Proc Natl Acad Sci U S A Date: 2003-02-05 Impact factor: 11.205
Authors: Yang Wang; Maha Saad; Refika I Pakunlu; Jayant J Khandare; Olga B Garbuzenko; Alexandre A Vetcher; Viatcheslav A Soldatenkov; Vitaly P Pozharov; Tamara Minko Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Laszlo M Hoesel; Michael A Flierl; Andreas D Niederbichler; Daniel Rittirsch; Shannon D McClintock; Jayne S Reuben; Matthew J Pianko; William Stone; Hongsong Yang; Milton Smith; J Vidya Sarma; Peter A Ward Journal: Antioxid Redox Signal Date: 2008-05 Impact factor: 7.468
Authors: Oleh Taratula; Olga B Garbuzenko; Paul Kirkpatrick; Ipsit Pandya; Ronak Savla; Vitaly P Pozharov; Huixin He; Tamara Minko Journal: J Control Release Date: 2009-06-28 Impact factor: 9.776
Authors: Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko Journal: Eur J Pharm Biopharm Date: 2012-12-08 Impact factor: 5.571
Authors: Henri de Martimprey; Jean-Rémi Bertrand; Claude Malvy; Patrick Couvreur; Christine Vauthier Journal: Pharm Res Date: 2010-01-20 Impact factor: 4.200